| MeSH term | MeSH ID | Detail |
|---|---|---|
| Mite Infestations | D008924 | 1 associated lipids |
| Polyendocrinopathies, Autoimmune | D016884 | 1 associated lipids |
| Leukoplakia | D007971 | 1 associated lipids |
| Fasciitis, Necrotizing | D019115 | 1 associated lipids |
| Mediastinal Emphysema | D008478 | 1 associated lipids |
| Malacoplakia | D008287 | 1 associated lipids |
| Myoclonic Cerebellar Dyssynergia | D002527 | 1 associated lipids |
| Lichen Nitidus | D017513 | 1 associated lipids |
| Lichenoid Eruptions | D017512 | 1 associated lipids |
| Lymphocele | D008210 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Connor A et al. | Generic tacrolimus in renal transplantation: trough blood concentration as a surrogate for drug exposure. | 2012 | Transplantation | pmid:23318306 |
| Plock JA et al. | Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells Prolong Graft Survival in Vascularized Composite Allotransplantation. | 2015 | Transplantation | pmid:26102613 |
| Gurk-Turner C et al. | Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. | 2008 | Transplantation | pmid:18497682 |
| Haririan A et al. | Polyomavirus reactivation in native kidneys of pancreas alone allograft recipients. | 2003 | Transplantation | pmid:12717201 |
| Arns W et al. | Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial. | 2017 | Transplantation | pmid:28658202 |
| Taber DJ et al. | Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. | 2017 | Transplantation | pmid:28658199 |
| Diémé B et al. | Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling. | 2014 | Transplantation | pmid:24598938 |
| Han DH et al. | Effect of sirolimus on calcineurin inhibitor-induced nephrotoxicity using renal expression of KLOTHO, an antiaging gene. | 2010 | Transplantation | pmid:20562737 |
| Stegall MD et al. | Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. | 1997 | Transplantation | pmid:9422404 |
| Shield CF et al. | Assessment of health-related quality of life in kidney transplant patients receiving tacrolimus (FK506)-based versus cyclosporine-based immunosuppression. FK506 Kidney Transplant Study Group. | 1997 | Transplantation | pmid:9422413 |
| Maruyama M et al. | Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. | 1990 | Transplantation | pmid:1696410 |
| Demmers MW et al. | Limited efficacy of immunosuppressive drugs on CD8+ T cell-mediated and natural killer cell-mediated lysis of human renal tubular epithelial cells. | 2014 | Transplantation | pmid:24704664 |
| Shibutani S et al. | Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. | 2005 | Transplantation | pmid:15849542 |
| Tory R et al. | Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations. | 2009 | Transplantation | pmid:19584682 |
| Weiler N et al. | Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. | 2010 | Transplantation | pmid:21048536 |
| Chisholm MA et al. | Renal transplant patient compliance with free immunosuppressive medications. | 2000 | Transplantation | pmid:11063348 |
| Dominguez J et al. | Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. | 2000 | Transplantation | pmid:11063349 |
| Busuttil RW et al. | General guidelines for the use of tacrolimus in adult liver transplant patients. | 1996 | Transplantation | pmid:8607197 |
| Atkison PR et al. | Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient. | 1997 | Transplantation | pmid:9311719 |
| Hoogduijn MJ et al. | Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. | 2008 | Transplantation | pmid:19005411 |
| Tzakis AG et al. | Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. | 2004 | Transplantation | pmid:15114087 |
| Talbot D et al. | Alopecia as a consequence of tacrolimus therapy in renal transplantation? | 1997 | Transplantation | pmid:9415574 |
| Gregory CR et al. | Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. | 1995 | Transplantation | pmid:7533955 |
| McDevitt-Potter LM et al. | A multicenter experience with generic tacrolimus conversion. | 2011 | Transplantation | pmid:21788920 |
| Gill JS et al. | Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. | 2010 | Transplantation | pmid:20098280 |
| Zhao W et al. | Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child. | 2012 | Transplantation | pmid:22450597 |
| Pascual J et al. | Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. | 2009 | Transplantation | pmid:19136902 |
| Ciancio G et al. | A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. | 2005 | Transplantation | pmid:16123718 |
| Vossen M et al. | Bone quality in swine composite tissue allografts: effects of combination immunotherapy. | 2005 | Transplantation | pmid:16123723 |
| Suzuki S et al. | Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. | 1993 | Transplantation | pmid:7685932 |
| McDiarmid SV et al. | Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. | 1993 | Transplantation | pmid:7685933 |
| Lauria MW et al. | Metabolic long-term follow-up of functioning simultaneous pancreas-kidney transplantation versus pancreas transplantation alone: insights and limitations. | 2010 | Transplantation | pmid:20061923 |
| Pascual M et al. | Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. | 1998 | Transplantation | pmid:9869086 |
| Strumph P et al. | The effect of FK506 on glycemic response as assessed by the hyperglycemic clamp technique. | 1995 | Transplantation | pmid:7542815 |
| Baran DA et al. | Tacrolimus in cardiac transplantation: efficacy and safety of a novel dosing protocol. | 2002 | Transplantation | pmid:12438960 |
| Kasahara M et al. | Role of HLA compatibility in pediatric living-related liver transplantation. | 2002 | Transplantation | pmid:12438966 |
| Hudnall SD | Cardiac hypertrophy postliver transplantation: a role for FK506 and cyclosporine A? | 2002 | Transplantation | pmid:12369583 |
| Higgins R et al. | Rises and falls in donor-specific and third-party HLA antibody levels after antibody incompatible transplantation. | 2009 | Transplantation | pmid:19300192 |
| Arai K et al. | Limb allografts in rats immunosuppressed with FK506. I. Reversal of rejection and indefinite survival. | 1989 | Transplantation | pmid:2479130 |
| Vathsala A et al. | The immunosuppressive antagonism of low doses of FK506 and cyclosporine. | 1991 | Transplantation | pmid:1713361 |
| Kawano K et al. | A protective effect of FK506 in ischemically injured rat livers. | 1991 | Transplantation | pmid:1713362 |
| de Jonge H et al. | Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. | 2010 | Transplantation | pmid:20592652 |
| Macphee IA et al. | Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. | 2005 | Transplantation | pmid:15729180 |
| Yuzawa K and Fukao K | Topical FK506 ointment for skin grafting. | 1998 | Transplantation | pmid:9565111 |
| Younes BS et al. | The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. | 2000 | Transplantation | pmid:10919581 |
| Higgins RM et al. | Conversion from tacrolimus to cyclosporin in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. | 2000 | Transplantation | pmid:10919600 |
| Cherikh WS et al. | A comparison of discharge immunosuppressive drug regimens in primary cadaveric kidney transplantation. | 2003 | Transplantation | pmid:12923430 |
| Zieliński A et al. | Simultaneous pancreas-kidney transplant from living related donor: a single-center experience. | 2003 | Transplantation | pmid:12923442 |
| Markus PM et al. | Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. | 1991 | Transplantation | pmid:1718063 |
| Ryu S and Yasunami Y | The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. | 1991 | Transplantation | pmid:1718064 |